Liege (Belgium) - October 29, 2009, 8:00 CET - OncoMethylome Sciences SA (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) announces today that it has received the following shareholder notification covering changes to the Transparency Declaration of the Company:
ING Fund Management B.V. has reduced its shareholding to less than 3% of the company’s shares
For further details on the transparency notifications received by the company, reference is made to our website www.oncomethylome.com
About OncoMethylome Sciences
OncoMethylome Sciences SA (Euronext Brussels: ONCOB; Euronext Amsterdam: ONCOA) is a molecular diagnostics company developing gene methylation tests to assist physicians in effectively detecting and treating cancer. Specifically, the company’s tests are designed to help the physician (i) accurately detect cancer in early stages of cancer development, (ii) predict a patient’s response to drug therapy, and (iii) predict the likelihood of cancer recurrence.
OncoMethylome Sciences SA boasts a broad product development pipeline and a solid partnering record. The company collaborates with leading international molecular oncology research centers, such as The Johns Hopkins University, and has a number of commercial and collaborative partnerships with Veridex LLC, a Johnson & Johnson company, LabCorp, Schering-Plough Corp., GlaxoSmithKline Biologicals, Abbott, Millipore Corporation’s BioScience Division, Merck KGaA, and Qiagen. OncoMethylome Sciences’ products are based on methylation technology invented by Johns Hopkins University (USA).
Established in January 2003, OncoMethylome Sciences SA has offices in Liege and Leuven (Belgium), in Durham, NC (USA), and in Amsterdam (the Netherlands).
For more information please contact: Philip Devine Tel. (+32) 4 364 20 70 ir@oncomethylome.com www.oncomethylome.com
